Drug Profile
DPK 060
Alternative Names: DPK-060Latest Information Update: 22 Nov 2017
Price :
$50
*
At a glance
- Originator DermaGen
- Developer DermaGen; Pergamum
- Class Antimicrobial cationic peptides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Atopic dermatitis; Otitis externa
Most Recent Events
- 14 Nov 2017 Promore Pharma out-licenses DPK 060 to Transdermal Therapeutic Technologies in USA
- 02 Oct 2015 No recent reports of development identified - Phase-II for Otitis externa in Sweden (Topical)
- 31 Dec 2012 Top-line efficacy and tolerability data from a phase II trial in Otitis externa released by Karolinska Development and Pergamum